Introduction {#Sec1}
============

Fluoropyrimidines are the backbone of first-line therapy for advanced gastric cancer \[[@CR1], [@CR2]\]. The novel fluoropyrimidine S-1 has quickly become the standard of care in Asia, but there is uncertainty about the role of S-1 in Western countries. Although S-1 is used with increasing frequency in Western countries, it has not fully replaced 5-fluorouracil (5-FU) and capecitabine. Meta-analyses have shown a marginally significant prolonged survival time and higher response rates for S-1 therapy compared with 5-FU therapy \[[@CR3]--[@CR5]\] but not for S-1 therapy compared with capecitabine therapy \[[@CR6]--[@CR9]\]. However, some of these reviews included retrospective studies, which may lead to bias of the overall effect observed or did not incorporate the newest evidence in this field \[[@CR10]--[@CR15]\]. For example, in addition to the FLAGS trial \[[@CR16]\], which was conducted in Western countries, the recently presented DIGEST trial \[[@CR11]\] can also shed light on the role of S-1 therapy in Western patients.

The use of doublets of cytotoxic agents versus singlets is associated with prolonged survival \[[@CR17]\] and therefore S-1-based combination therapy versus S-1 monotherapy has been investigated in several large trials in Asia. Previous meta-analyses have indicated that combination therapy significantly prolonged survival over monotherapy, but generally combination therapy was more toxic \[[@CR18], [@CR19]\]. However, the final results of four randomized studies, including the pivotal START trial, which was the first phase III trial to compare S-1 combined with a taxane with S-1 alone, were not included in these reviews \[[@CR12], [@CR13], [@CR20], [@CR21]\]. Moreover, it is also still an open question if there are predictive factors to define which patient subgroups will benefit most from S-1 combination therapy compared with S-1 monotherapy.

Therefore, the objectives of our study were to systematically review all available literature on randomized clinical trials to investigate the efficacy and toxicity by means of meta-analysis of S-1-based therapy compared with 5-FU- and capecitabine-based therapy and of S-1-based combination therapy compared with S-1 monotherapy.

Methods {#Sec2}
=======

Study protocol {#Sec3}
--------------

The protocol of this review has been published in the international prospective register of systematic reviews (PROSPERO): [http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014010654](http://www.crd.york.ac.uk/PROSPERO/display_record.asp%3fID%3dCRD42014010654).

Literature search {#Sec4}
-----------------

For the searching of the electronic databases \[MEDLINE, Embase and Cochrane Central Register of Controlled Trials (CENTRAL)\], a sensitive search strategy without date restriction was applied using the medical subject headings of 'S-1' and 'gastric cancer'; thereafter, the results were filtered for clinical trials. ClinicalTrials.gov (<http://www.clinicaltrials.gov>) was searched for the term 'S-1' within the topic 'stomach neoplasm' and the results were filtered for phase II and phase III trials. In addition, all meeting abstracts from the American Society of Clinical Oncology and European Society for Medical Oncology up to May 2015 were searched via <http://www.ascopubs.org/search> and <http://annonc.oxfordjournals.org/search>, respectively, for the following terms: 'S-1' and 'gastric'. The full search history is available in Document S1 in the electronic supplementary material. Two reviewers (E.t.V. and M.S.) reviewed the literature independently, and discrepancies were resolved by discussion with an arbiter (N.H.M.) until consensus was reached. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.

Inclusion criteria {#Sec5}
------------------

Studies had to meet the following eligibility criteria: (1) included patients with pathologically proven advanced gastric cancer (recurrent or unresectable disease); (2) first-line palliative (a) S-1-based therapy (monotherapy or doublet therapy) compared with 5-FU- or capecitabine-based chemotherapy (monotherapy or doublet therapy ) or (b) S-1-based combination chemotherapy compared with S-1 monotherapy; and (3) prospective phase II or phase III randomized controlled trials.

Outcomes and data extraction {#Sec6}
----------------------------

The primary efficacy outcome was overall survival (OS). To identify potential predictive factors for the efficacy of S-1 combination therapy compared with S-1 monotherapy, subgroup data were extracted for OS if possible. Secondary efficacy outcomes were progression-free survival (PFS) and overall response rate (ORR), defined as the sum of both partial and complete responses according to the Response Evaluation Criteria in Solid Tumors (RECIST). Tolerability outcomes comprised the incidence of adverse events (AEs) divided into mild toxicity (grade 1--2 AEs) and severe toxicity (grade 3--4 AEs). In all studies, AEs were scored according to the National Cancer Institute Common Toxicity Criteria (<http://ctep.cancer.gov>). Two reviewers (E.t.V. and N.H.M.) were involved in data extraction; discrepancies were resolved by discussion with an arbiter (L.N.) until consensus was reached.

Study quality assessment {#Sec7}
------------------------

Two reviewers (E.t.V. and N.H.M.) independently examined the quality of all included studies using the Cochrane risk of bias tool (*Cochrane Handbook for Systematic Reviews of Interventions*, version 5.1.0) until consensus was reached. Studies with a high risk of bias were not included in the analysis. Since the primary outcome, OS, would not be influenced by the absence of a blinded imaging review, this item was not scored as unknown or high risk of bias for OS. Single-centre studies and studies without a published full article were rated as unclear risk of other possible bias. To assess the effect of study quality on the pooled estimate, sensitivity analyses were conducted by (1) omission of studies described in conference reports only and (2) omission of studies stepwise according to unknown risk of bias rating on one item, on two items and on three or more items.

Statistical analysis {#Sec8}
--------------------

Pairwise meta-analyses using random-effect models were conducted with the Metagen R package \[[@CR22]\] and Review Manager 5.3. For OS and PFS outcomes, hazard ratios (HRs) and 95 % confidence intervals (CIs) were extracted by the method described by Tierney et al. \[[@CR23]\]. An HR less than 1 indicates a beneficial effect for the experimental arm, and an HR of 0.80 or less was considered clinically meaningful \[[@CR24]\]. In addition, stratified HRs for OS in the patient subgroups were pooled with meta-analysis, and subgroup differences were statistically tested with chi-square tests. Risk ratios (RRs) were calculated for ORR (an RR greater than 1 indicates a beneficial effect for the experimental arm) and for event counts of grade 1--2 and grade 3--4 toxicity in both arms (an RR less than 1 indicates a beneficial effect for the experimental arm).

Statistical heterogeneity was tested with the Cochran Q test and quantified by the *I*^2^ index. Substantial heterogeneity (*I*^2^ ≥ 30 %) was explored by subgroup and sensitivity analyses. We tested for funnel plot asymmetry by regressing study outcomes on the standard error of the effect size \[[@CR25]\]. All analyses were based on the intention-to-treat population of the included studies. All tests were performed two-sided, and a *P* value of less 0.05 was considered statistically significant.

Results {#Sec9}
=======

Literature search and study quality {#Sec10}
-----------------------------------

Three hundred and fifty-four unique references were identified through our searching MEDLINE, Embase and CENTRAL until May 2015, from which 326 were excluded after abstract screening, because of ineligibility according to the criteria for this review. Of the 28 reports remaining for full-text screening, four studies were eligible to assess S-1-based versus 5-FU-based therapy \[[@CR26]--[@CR29]\], two studies were eligible to assess S-1-based versus capecitabine-based therapy \[[@CR30], [@CR31]\] ,and six studies were eligible to assess S-1 combination therapy versus S-1 monotherapy \[[@CR21], [@CR32]--[@CR35]\]. Searching ClinicalTrials.gov and the American Society of Clinical Oncology and European Society for Medical Oncology libraries provided additional reports of four unpublished phase III studies \[[@CR11], [@CR12], [@CR14], [@CR15]\] and two phase II studies \[[@CR10], [@CR13]\]. The total number of studies included was 18 (Fig. S1).

There were no major differences in study and patient characteristics among the studies included (Table [1](#Tab1){ref-type="table"}), although one study included patients with diffuse gastric cancer only \[[@CR11]\]. For the primary outcome, seven studies were rated as low risk of bias \[[@CR28]--[@CR34]\], whereas 11 studies were rated as unclear risk of bias because of the lack of information on one item (three studies) \[[@CR12], [@CR21], [@CR35]\] or two items (three studies) \[[@CR20], [@CR27]\] or abstract and insufficient information for risk of bias assessment (five studies) \[[@CR10], [@CR11], [@CR13]--[@CR15]\] (Fig. S2).Table 1Study and patient baseline characteristicsStudyPhaseRegionCentreEnrolmentArm*N*MenMedian age^a^ (range)Ajani et al. \[[@CR26]\]IIIWestern countriesMulticentreMay 2005 to Mar 2007S-1 + Cis521382 (73 %)59 (18--83)5-FU + Cis508347 (68 %)60 (20--85)Ajani et al. \[[@CR11]\]IIIWestern countriesMulticentreApr 2011 to Feb 2014S-1 + Cis239124 (52 %)56 (25--86)5-FU + Cis12260 (49 %)56 (27--83)Boku et al. \[[@CR29]\]IIIJapanMulticentreNov 2000 to Jan 2006S-1234175 (75 %)64 (58--69)5-FU234176 (75 %)64 (57--69)Huang et al. \[[@CR27]\]IIChinaMulticentreNov 2007 to Apr 2010S-1 + PTX11989 (75 %)56 (18--74)5-FU + PTX11076 (69 %)54 (19--72)Jin et al. \[[@CR12]\]IIIChinaMulticentreJul 2005 to Oct 2006S-1 + Cis7455 (74 %)57 (24--80)S-17756 (73 %)57 (32--82)5-FU + Cis7361 (84 %)58 (33--77)Kim et al. \[[@CR31]\]IIKoreaMulticentreMar 2008 to Sep 2009S-1 + Ox6544 (68 %)60 (28--77)Cap + Ox6445 (70 %)61 (20--75)Kobayashi et al. \[[@CR10]\]IIJapanMulticentreNov 2011 to Jun 2013S-1 + Cis5430 (55 %)65 (44--74)Cap + Cis5545 (81 %)65 (25--74)Koizumi et al. \[[@CR32]\]IIIJapanMulticentreMar 2001 to Nov 2006S-1 + Cis148108 (73 %)62 (33--74)S-1150116 (71 %)62 (28--74)Koizumi et al. \[[@CR20]\]IIIJapan and KoreaMulticentreSep 2005 to Sep 2008S-1 + DTX314227 (72 %)65 (23--79)S-1321229 (71 %)65 (27--79)Komatsu et al. \[[@CR34]\]IIJapanMulticentreAug 2003 to Apr 2007S-1 + IRI4834 (71 %)70 (47--78)S-14737 (79 %)63 (24--76)Lee et al. \[[@CR30]\]IIKoreaMulticentreOct 2004 to Apr 2006S-14537 (82 %)71 (65--82)Cap4630 (65 %)71 (66--78)Lu et al. \[[@CR21]\]IIChinaSingle centreJan 2008 to Dec 2011S-1 + Ox4734 (72 %)63 (37--75)S-14733 (70 %)65 (34--74)Narahara et al. \[[@CR33]\]IIIJapanMulticentreJun 2004 to Apr 2007S-1 + IRI155110 (71 %)63 (33--75)S-1160127 (79 %)63 (27--75)Nishikawa et al. \[[@CR28]\]IIKoreaMulticentreDec 2005 to Nov 2008S-1 + PTX7753 (69 %)67 (40--82)5-FU + PTX8060 (75 %)67 (47--90)Wang et al. \[[@CR35]\]IIChinaSingle centreJan 2009 to Dec 2011S-1 + PTX4132 (78 %)63 (35--74)S-14130 (73 %)61 (31--73)Sawaki et al. \[[@CR15]\]IIIJapanMulticentreMay 2002 to Aug 2006S-18866 (75 %)63 (32--77)5-FU + Lv8971 (80 %)65 (44--77)Xu et al. \[[@CR14]\]IIIChinaMulticentreSep 2008 to Dec 2011S-1 + Cis12084 (70 %)53 (25--76)5-FU + Cis11885 (73 %)55 (21--76)Yamaguchi et al. \[[@CR13]\]IIJapanMulticentreOct 2011 to Dec 2012S-1 + Cis4838 (79 %)65S-1 + Lv4733 (70 %)65Ox + S-1 + Lv4737 (79 %)65StudyECOG PS ≥2MetastaticRegimen2nd lineMedian no. of cyclesMedian OS (months)Median PFS (months)Ajani et al. \[[@CR26]\]0 (0 %)497 (96 %)S-1 50 mg/m^2^ days 1--21 + Cis 75 mg/m^2^ day 1 q4w154 (30 %)48.64.80 (0 %)488 (96 %)5-FU 1000 mg/m^2^/24 h days 1--5 + Cis 100 mg/m^2^ day 1 q4w169 (33 %)47.95.5Ajani et al. \[[@CR11]\]0 (1 %)239 (100 %)S-1 50 mg/m^2^ days 1--21 + Cis 75 mg/m^2^ day 1 q4wNANA7.54.40 (0 %)122 (100 %)5-FU 800 mg/m^2^ days 1--5 + Cis 80 mg/m^2^ days1 q3wNANA6.63.9Boku et al. \[[@CR29]\]3 (1 %)234 (100 %)S-1 80 mg/m^2^ days 1--28 q6w173 (74 %)NA11.44.23 (1 %)234 (100 %)5-FU 800 mg/m^2^ days 1--5 q4w194 (83 %)NA10.82.9Huang et al. \[[@CR27]\]Median KPS 80112 (94 %)S-1 80--120 mg/day days 1-14 + PTX 60 mg/m^2^ days 1, 8, and 15 q4wNA99 days (median exposure)NA153Median KPS 80102 (93 %)5-FU 500 mg/m^2^ days 1--5 + Lv 20 mg/m^2^ days 1--5 + PTX 60 mg/m^2^ days 1, 8, and 15 q4wNA77 days (median exposure)NA129Jin et al. \[[@CR12]\]8 (11 %)74 (100 %)S-1 80 mg/m^2^ days 1--21 + Cis 60 mg/m^2^ day 8 q5wNA4.08^b^14.2NA12 (16 %)77 (100 %)S-1 80 mg/m^2^ days 1--28 q6wNA3.25^b^8.8NA10 (14 %)73 (100 %)5-FU 600 mg/m^2^ days 1--5 + Cis 20 mg/m^2^ days 1--5 q4w41 (56 %)2.77^b^10.5NAKim et al. \[[@CR31]\]0 (0 %)47 (72 %)S-1 80 mg/m^2^ days 1--14 + Ox 130 mg/m^2^ day 1 q3w39 (60 %)612.46.2^c^0 (0 %)46 (72 %)Cap 2000 mg/m^2^ days 1--14 + Ox 130 mg/m^2^ day 1 q3w40 (62 %)813.37.2^c^Kobayashi et al. \[[@CR10]\]1 (2 %)54 (100 %)S-1 80 mg/m^2^ days 1--21 + Cis 60 mg/m^2^ day 8 q5wNANA8.33.62 (4 %)55 (100 %)Cap 2000 mg/m^2^ days 1--14 + Cis 80 mg/m^2^ day 1 q3wNANA8.03.3Koizumi et al. \[[@CR32]\]4 (3 %)148 (100 %)S-1 80--120 mg/day days 1--21 + Cis 60 mg/m^2^ day 8 q5w110 (74 %)413.06.05 (3 %)150 (100 %)S-1 80--120 mg/day days 1--28 q6w113 (75 %)311.04.0Koizumi et al. \[[@CR20]\]0 (0 %)314 (100 %)S-1 80--120 mg/day days 1-14 + DTX 40 mg/m^2^ day 1 q3w219 (70 %)NA12.55.30 (0 %)321 (100 %)S-1 80 mg/m^2^ days 1--28 q6w244 (76 %)NA10.84.2Komatsu et al. \[[@CR34]\]0 (0 %)48 (100 %)S-1 80--120 mg/m^2^ days 1-14 + IRI 75 mg/m^2^ days 1--15 q4wNA39.14.9^c^0 (0 %)47 (100 %)S-1 80--120 mg/m^2^ days 1--14 q4wNA212.33.8^c^Lee et al. \[[@CR30]\]2 (4 %)45 (100)S-1 80--120 mg/day days 1--28 q6wNA28.14.24 (9 %)46 (100 %)Cap 2500 mg/m^2^ days 1--14 q3wNA59.54.7Lu et al. \[[@CR21]\]5 (11 %)47 (100 %)S-1 80--120 mg/day days 1--14 + Ox 130 mg/m^2^ day 1 q3wNA614.06.54 (9 %)47 (100 %)S-1 80--120 mg/day days 1-14 q3wNA411.04Narahara et al. \[[@CR33]\]5 (3 %)155 (100 %)S-1 80--120 mg/day days 1--21 + IRI 80 mg/m^2^ days 1--15 q5w128 (83 %)412.8NA5 (3 %)160 (100 %)S-1 80--120  mg/day days 1--28 q6w112 (70 %)310.5NANishikawa et al. \[[@CR28]\]0 (0 %)77 (100 %)Sequential: S-1 80 mg/m^2^ days 1--28 q6w; progression PTX 50 mg/m^2^ days 1, 8, and 15 q3w; Concurrent: S-1 80 mg/m^2^ days 1-14 + PTX 50 mg/m^2^ days 1, 8, and 15 q3w14 (18 %)Seq: S-1 6\
, PTX 4; Conc: 7.515.2NA0 (0 %)80 (100 %)Sequential: 5-FU 800 mg/m^2^, days 1--5; progression PTX 80 mg/m^2^, days 1, 8, and 15 q4w\
Concurrent: 5-FU 600 mg/m^2^ days 1-5 + PTX 80 mg/m^2^ days 1, 8, and 15, 22 q4w17 (21 %)Seq: 5-FU 4, PTX 3; Conc: 614.2NAWang et al. \[[@CR35]\]4 (10 %)41 (100 %)S-1 80--120 mg/day days 1-14 + PTX 60 mg/m^2^ days 1, 8, and 15 q4w\>50 %614.063 (7 %)41 (100 %)S-1 80--120 mg/day days 1--14 q4w\>50 %511.04Sawaki et al. \[[@CR15]\]3 (3 %)68 (77 %)S-1 80--120 mg/day days 1--28 q6wNANA8.33.54 (4 %)65 (73 %)5-FU 600 mg/m^2^ bolus days 1, 8, 15, 22, 29, and 36 + Lv 250 mg/m q8wNANA10.34.0Xu et al. \[[@CR14]\]7 (6 %)120 (100 %)S-1 80 mg/m^2^ days 1--21 + Cis 20 mg/m^2^ days 1--4 q5wNA610.05.54 (3 %)118 (100 %)5-FU 800 mg/m^2^ days 1-5 + Cis 20 mg/m^2^ days 1-4 q4wNA610.54.6Yamaguchi et al. \[[@CR13]\]0 (0 %)48 (100 %)S-1 80--120 mg/day days 1--21 + Cis 60 mg/m^2^ day 8 q5w33 (70 %)NA12.65.60 (0 %)47 (100 %)S-1 80--120 mg/day days 1--7 + Lv 50 mg/m^2^ days 1--7 q2w36 (77 %)NA18.48.30 (0 %)47 (100 %)S-1 80--120 mg/day days 1--7 + Lv 50 mg/m^2^ days 1--7 + Ox 85 mg/m^2^ day 1 q2w35 (73 %)NA15.64.2*Cap* capecitabine, *Cis* cisplatin, *Conc* concurrent, *DTX* docetaxel, *ECOG PS* Eastern Cooperative Oncology Group performance status, *5-FU* 5-fluorouracil, *IRI* irinotecan, *KPS* Karnofsky performance status, *Lv* leucovorin, *NA* not available, *OS* overall survival, *Ox* oxaliplatin, *PFS* progression-free survival, *PTX* paclitaxel, *q2w* every 2 weeks, *q3w* every 3 weeks, *q4w* every 4 weeks, *q5w* every 5 weeks, *q6w* every 6 weeks, *q8w* every 8 weeks, *Seq* sequential^a^The range is given in *parentheses*^b^The mean number of cycles was given instead of the median number of cycles received^c^The median time to progression was given

S-1-based therapy versus 5-FU- and capecitabine-based therapy {#Sec11}
-------------------------------------------------------------

Eleven studies (*n* = 3135) were included in the meta-analysis: 1636 patients received S-1-based therapy, 1334 patients received 5-FU-based therapy (eight studies) and 165 patients received capecitabine-based therapy (three studies). Nine studies were conducted in Asia (*n* = 1745) and two studies were conducted in Western countries (*n* = 1372) (Table [1](#Tab1){ref-type="table"}). We were able to extract OS and PFS data from ten and six studies. respectively, whereas ORR data were available from all 11 studies.

Compared with 5-FU-based therapy, S-1-based therapy showed no difference in OS (HR 0.92, 95 % CI 0.82--1.03, *P* = 0.16) and PFS (HR 0.88, 95 % CI 0.73--1.08, *P* = 0.22), but there was a significant increase in ORR (RR 1.43, 95 % CI 1.05--1.96, *P* = 0.02) (Fig. [1](#Fig1){ref-type="fig"}). No statistically significant subgroup differences were found between Asian and Western patients in terms of OS (*P* = 0.85), PFS (*P* = 0.55) and ORR (*P* = 0.63) (Fig. [2](#Fig2){ref-type="fig"}). In the Asian population, S-1-based therapy was superior in terms of ORR compared with 5-FU-based therapy (*P* = 0.02), whereas in the Western population, statistical significance was not reached (*P* = 0.52). No significant heterogeneity was detected for OS (*I*^2^ = 26 %, *P* = 0.23); for both PFS and ORR, heterogeneity was present, with *I*^2^ = 72 % (*P* \< 0.01) and *I*^2^ = 78 % (*P* \< 0.001).Fig. 1S-1-based therapy compared with 5-fluorouracil (*5-FU*)- and capecitabine (*Cap*)-based therapy: **a** overall survival; **b** progression-free survival; **c** overall response rate. *CI* confidence interval, *Cis* cisplatin, *df* degrees of freedom, *E* effect, *H* heterogeneity, *HR* hazard ratio, *Lv* leucovorin, *Ox* oxaliplatin, *PTX* paclitaxel, *RR* risk ratio, *SE* standard errorFig. 2S-1-based therapy compared with 5-fluorouracil (*5-FU*)-based therapy for Asian and Western patient subgroups: **a** overall survival; **b** progression-free survival; **c** overall response rate. *Cap* capecitabine, *CI* confidence interval, *Cis* cisplatin, *df* degrees of freedom, *E* effect, *H* heterogeneity, *HR* hazard ratio, *Lv* leucovorin, *PTX* paclitaxel, *RR* risk ratio, *SE* standard error

Compared with capecitabine-based therapy, S-1-based therapy showed no difference in OS (HR 1.03, 95 % CI 0.79--1.35, *P* = 0.81), PFS (HR 0.76, 95 % CI 0.50--1.16, *P* = 0.20) and ORR (RR 0.92, 95 % CI 0.67--1.27, *P* = 0.61) (Fig. [2](#Fig2){ref-type="fig"}). No statistically significant heterogeneity was detected.

For both comparisons, sensitivity analysis showed that the direction of the overall results was not influenced by omission of studies reported in conference abstracts only, by omission of studies stepwise according to their risk of bias, or by omission of two studies that had leucovorin in the 5-FU arm, which was the case in the studies of Sawaki et al. \[[@CR15]\] and Huang et al. \[[@CR27]\]. This indicates that the results are robust regarding study quality and concomitant administration of leucovorin (Table S1).

For S-1 compared with 5-FU, data were available for four haematological and 14 non-haematological grade 1--2 AEs and for five haematological and 16 non-haematological grade 3--4 AEs (Table [2](#Tab2){ref-type="table"}). In the Western subgroup, S-1-based therapy showed significantly lower rates of febrile neutropenia, toxicity-related deaths, grade 3--4 stomatitis and mucositis and grade 1--2 diarrhoea, stomatitis and alopecia compared with 5-FU-based therapy. The rates of grade 1--2 neutropenia and hand--foot syndrome were greater with S-1 than with 5-FU.Table 2Toxicity results of S-1-based therapy compared with 5-fluorouracil (*5-FU*)-based therapyGrade 1--2 adverse eventsWestern studiesAsian studiesS-1-based therapy5-FU-based therapyEstimateHeterogeneityS-1-based therapy5-FU-based therapyEstimateHeterogeneity*nNnN*RR^a^*P*Trials*I* ^2^ (%)*PnNnN*RR^a^*P*Trials*I* ^2^ (%)*P*Haematological Neutropenia143751696261.42 (1.10--1.84)0.008\*200.811063321273180.80 (0.65--0.98)0.03\*300.88 Leucopenia1827511076261.10 (0.92--1.32)0.30200.991613321793180.85 (0.68--1.07)0.173560.10 Anaemia2687152016261.00 (0.87--1.16)0.95200.491063321133180.92 (0.76--1.11)0.37300.54 Thrombocytopenia2907512616260.98 (0.57--1.71)0.96293\<0.001\*37121261181.39 (0.90--2.14)0.141NANANon-haematological Nausea3967513516260.95 (0.86--1.05)0.32200.571163321553180.72 (0.57--0.91)0.005\*3330.22 Vomiting2817512626261.00 (0.72--1.37)0.982660.09833321023180.75 (0.51--1.11)0.153560.10 Diarrhoea1677511936260.77 (0.60--0.99)0.05\*2260.2567332803180.84 (0.53--1.33)0.463590.09 Mucositis357511266260.30 (0.06--1.39)0.12293\<0.001\*NANANANANANANANANA Stomatitis307511006260.24 (0.12--0.48)\<0.001\*2420.1927213372080.68 (0.27--1.68)0.402710.06 Anorexia1335211495080.87 (0.71--1.06)0.171NANA1253321363180.88 (0.73--1.05)0.16300.85 Fatigue1767511566260.98 (0.79--1.22)0.852110.2934211462000.71 (0.32--1.62)0.422750.05 Asthenia43230241180.92 (0.59--1.44)0.711NANANANANANANANANANANA Hand--foot syndrome27521115082.39 (1.20--4.27)0.01\*1NANANANANANANANANANANA Neuropathy33751436260.56 (0.30--1.06)0.072480.17311911102.77 (0.29--26.27)0.371NANA Alopecia315211035080.29 (0.20--0.43)\<0.001\*1NANA21119131101.49 (0.79--2.84)0.221NANA Weight loss1657511496260.96 (0.79--1.17)0.72200.36229239900.55 (0.36--0.85)0.007\*1NANA Constipation37230171181.12 (0.66--1.90)0.681NANA34240422280.74 (0.38--1.43)0.372550.14Abdominal pain124751976261.14 (0.81--1.61)0.442230.251712171182.37 (1.02--5.50)0.04\*2NANAGrade 3--4 adverse eventsWestern studiesAsian studiesS-1-based therapy5-FU-based therapyEstimateHeterogeneityS-1-based therapy5-FU-based therapyEstimateHeterogeneity*nNnN*RR^a^*P*Trials*I* ^2^ (%)*PnNnN*RR^a^*P*Trials*I* ^2^ (%)*P*Haematological Neutropenia1577512316260.70 (0.30--1.63)0.41293\<0.001\*140722857011.36 (0.66--2.77)0.40684\<0.001\* Leucopenia57751806260.66 (0.37--1.17)0.162530.1584722437011.56 (0.81--2.98)0.186610.02\* Anaemia1187511066261.30 (0.47--3.60)0.622860.008\*95722697011.42 (0.83--2.43)0.216590.03\* Thrombocytopenia37751446261.33 (0.20--8.95)0.772720.0624227142691.67 (0.38--7.36)0.503710.03\* Febrile neutropenia9521355080.25 (0.12--0.52)\<0.001\*1NANA235303422.87 (0.30--27.47)0.36200.98Non-haematological Nausea50751536260.83 (0.57--1.21)0.34200.3325630326110.76 (0.46--1.28)0.30500.98 Vomiting52751546260.85 (0.59--1.23)0.39200.5713488224690.59 (0.30--1.14)0.12500.92 Diarrhoea28751256261.03 (0.61--1.75)0.91200.7441722167012.03 (0.65--6.35)0.226630.02\* Mucositis5751466260.10 (0.04--0.24)\<0.001\*200.95NANANANANANANANANA Stomatitis7751726260.10 (0.05--0.20)\<0.001\*200.856527145170.45 (0.18--1.13)0.09400.95 Anorexia40751356260.97 (0.63--1.51)0.90200.3747722507010.94 (0.64--1.37)0.74600.77 Fatigue88751726261.37 (0.54--3.49)0.512730.051544554322.71 (1.02--7.21)0.05\*300.71 Asthenia13230121180.53 (0.23--1.20)0.131NANANANANANANANANANANA Hand--foot syndrome152125080.49 (0.04--5.36)0.561NANA323402347.00 (0.36--134.77)0.201NANA Neuropathy475146260.72 (0.17--3.18)0.67200.34531423091.97 (0.43--9.04)0.38200.49 Alopecia052115080.33 (0.01--7.96)0.491NANA411921101.85 (0.35--9.89)0.471NANA Weight loss23751336260.65 (0.39--1.09)0.10200.810802770.19 (0.01--3.95)0.291NANA Constipation223001182.58 (0.12--53.22)0.541NANA012111180.33 (0.01--7.90)0.491NANA Abdominal pain51751296261.62 (0.82--3.20)0.172220.26212101184.88 (0.24--100.52)0.301NANASerious adverse events1707511826260.83 (0.55--1.23)0.352720.06411921101.85 (0.35--9.89)0.471NANAToxicity-related death14571266260.51 (0.27--0.96)0.04\*200.99235313421.52 (0.19--12.30)0.69200.59A risk ratio (*RR*) greater than 1 represents a beneficial effect of S-1-based therapy*NA* not available\**P* \< 0.05^a^The 95 % confidence interval is given in *parentheses*

In the Asian subgroup, S-1-based therapy showed a significantly increased incidence of grade 3--4 fatigue and grade 1--2 abdominal pain but a lower incidence of grade 1--2 neutropenia, nausea and weight loss compared with 5-FU-based therapy. The incidence of febrile neutropenia, serious AEs or toxicity-related deaths was not different between both arms.

For S-1 compared with capecitabine, data were available for four haematological and 13 non-haematological grade 1--2 AEs and for five haematological and 12 non-haematological grade 3--4 AEs (Table [3](#Tab3){ref-type="table"}). Lower rates of grade 3--4 neutropenia and grade 1--2 hand--foot syndrome were found with S-1-based therapy compared with capecitabine-based therapy. The incidence of febrile neutropenia, serious AEs or toxicity-related deaths was not different between both arms.Table 3Toxicity results of S-1-based therapy compared with capecitabine-based therapyGrade 1--2Grade 3--4S-1-based therapyCapecitabine-based therapyEstimateHeterogeneityS-1-based therapyCapecitabine-based therapyEstimateHeterogeneity*nNnN*RR^a^*P*Trials*I* (%)*PnNnN*RR^a^*P*Trials*I* (%)*P*Haematological Neutropenia59163651630.91 (0.69--1.19)0.50300.3913163251630.52 (0.27--0.97)0.04\*300.93 Leucopenia42107411081.05 (0.65--1.71)0.832390.20610731081.98 (0.50--7.90)0.33200.60 Anaemia1261631321630.94 (0.84--1.05)0.29300.3823163181631.31 (0.57--3.01)0.523420.18 Thrombcytopenia68163771630.87 (0.69--1.10)0.24300.5311163111631.02 (0.47--2.20)0.97300.77 Febrile neutropeniaNANANANANANANANANA316331631.03 (0.22--4.93)0.97300.69Non-haematological Nausea83163711631.19 (0.90--1.58)0.232360.21816391630.8 (0.31--2.07)0.65300.43 Vomiting46163461630.98 (0.61--1.56)0.923400.19416341630.97 (0.25--3.75)0.96300.66 Diarrhoea45163451630.99 (0.70--1.41)0.98300.61916341631.55 (0.24--10.16)0.653440.17 MucositisNANANANANANANANANA2650644.92 (0.24--100.60)0.301NANA Stomatitis239836990.67 (0.23--1.90)0.452800.02\*0562550.20 (0.01--4.00)0.291NANA Anorexia88163971630.89 (0.74--1.07)0.21300.5016163121631.34 (0.66--2.71)0.42300.95 Fatigue225623550.94 (0.60--1.47)0.791NANA3563550.98 (0.21--4.66)0.981NANA Asthenia57107571081.04 (0.83--1.30)0.73200.58410791100.50 (0.14--1.78)0.292100.29 Hand--foot syndrome14163591630.25 (0.15--0.43)\<0.001\*300.52016351630.25 (0.04--1.46)0.12300.92 Neuropathy28121391190.56 (0.17--1.80)0.332710.062653640.66 (0.11--3.80)0.641NANA Alopecia0564550.11 (0.01--1.98)0.131NANANANANANANANANANANA Weight loss135611551.16 (0.57--2.36)0.681NANA1561550.98 (0.06--15.31)0.991NANA Constipation0561550.33 (0.01--7.87)0.491NANANANANANANANANANANA Abdominal pain279824991.16 (0.62--2.16)0.642350.225981993.75 (0.63--22.27)0.15200.86A risk ratio (*RR*) greater than 1 represents a beneficial effect S-1-based therapy*NA* not available\* *P* \< 0.05^a^The 95 % confidence interval is given in *parentheses*

S-1-based combination therapy versus S-1 monotherapy {#Sec12}
----------------------------------------------------

For this comparison, eight studies (*n* = 1808) were included in the meta-analysis, with 927 and 881 patients in the S-1 combination therapy group and the S-1 monotherapy group, respectively. Four different combination therapies were compared with S-1 monotherapy: S-1 plus cisplatin therapy (*n* = 544 patients, three studies), S-1 plus oxaliplatin therapy (*n* = 190, two studies), S-1 plus taxane therapy (*n* = 717, two studies) and S-1 plus irinotecan therapy (*n* = 404, two studies). All studies were conducted in Asia: three studies in China, four studies in Japan, and one study in both Japan and Korea (Table [1](#Tab1){ref-type="table"}). We extracted the HRs and 95 % CIs from seven studies for OS and from five studies for PFS. ORRs were available from all eight studies.

The pooled estimates of S-1 combination therapy versus S-1 monotherapy were superior for OS (HR 0.76, 95 % CI 0.65--0.89, *P* \< 0.001), PFS (HR 0.68, 95 % CI 0.56--0.82, *P* \< 0.001) and ORR (RR 1.51, 95 % CI 1.32--1.74, *P* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}). Subgroup analyses showed that ORR was significantly better for all four combination therapies and showed no evidence of heterogeneity (*I*^2^ = 0 %, *P* = 0.95). However, only S-1 plus oxaliplatin therapy showed significant estimates for both OS and PFS compared with S-1 monotherapy, whereas OS was not significant for S-1 combined with irinotecan, cisplatin or a taxane. PFS was statistically significant for S-1 plus taxane therapy, but not for S-1 plus cisplatin therapy or S-1 plus irinotecan therapy.Fig. 3S-1-based combination therapy compared with S-1 monotherapy: **a** overall survival; **b** progression-free survival; **c** overall response rate. *CI* confidence interval, *Cis* cisplatin, *df* degrees of freedom, *DTX* docetaxel, *E* effect, *H* heterogeneity, *HR* hazard ratio, *IRI* irinotecan, *Lv* leucovorin, *NA* not available, *Ox* oxaliplatin, *PTX* paclitaxel, *RR* risk ratio, *SE* standard error

Heterogeneity was explored in subanalyses and sensitivity analyses (Table S2). For the cisplatin-based and taxane-based subgroup analyses, the non-significant effect might by due to some heterogeneity among the studies (OS *I*^2^ = 45.0 %, *P* = 0.08; PFS *I*^2^ = 44 %, *P* = 0.11). When studies were stratified according to region, a significant subgroup difference between Chinese studies and Japanese studies was found in OS (*P* \< 0.005). No subgroup differences for region were found in PFS (*P* = 0.38) and ORR (*P* = 0.88). Furthermore, no significant fluctuations in the overall results were detected with sensitivity analysis according to study quality and concomitant administration of leucovorin, which was the case with the comparison of S-1 plus cisplatin therapy with S-1 plus leucovorin therapy in the study of Yamaguchi et al. \[[@CR13]\].

Data were available for four haematological and 12 non-haematological grade 1--2 AEs and for five haematological and 11 non-haematological grade 3--4 AEs. Compared with S-1 monotherapy, S-1-based doublets were associated with an increased rate of grade 3--4 neutropenia, leucopenia and stomatitis and with an increased rate of grade 1--2 leucopenia, anaemia, thrombocytopenia, lymphocytopenia, anorexia, fatigue and alopecia (Table S3).

To identify subgroups that may benefit most from S-1 combination therapy compared with S-1 monotherapy, three large phase III Japanese studies (*n* = 1248) reporting a stratified analysis for OS could be used (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR32], [@CR33]\]. The pooled effect size for these three studies was HR 0.82 (95 % CI 0.72--0.93). A trend toward significant subgroup differences in favour of S-1 combination therapy was found in favour of patients with diffuse-type histological features compared with patients with intestinal-type histological features (*P* = 0.06; HR \< 0.80) and patients with measurable disease compared with patients with non-measurable disease (*P* = 0.06; HR \< 0.80). Furthermore, subgroups with peritoneal metastases showed a non-significant but clinically relevant HR (0.80 or less) in favour of S-1 combination therapy. No other potential predictive factors were identified.Fig. 4Stratified overall survival (OS) results for S-1 combination therapy versus S-1 monotherapy. Forest plot of OS results for S-1-based combination therapy versus S-1 monotherapy stratified per patient subgroup. For target tumour more than three studies are shown because these studies included only patients with measurable lesions. Pooled sample sizes are stated for S-1 combination therapy and S-1 monotherapy groups if separate sample sizes were not available in the study report.  *CI* confidence interval, *Cis* cisplatin, *df* degrees of freedom, *DTX* docetaxel, *E* effect, *ECOG* Eastern Cooperative Oncology Group performance status, *H* heterogeneity, *HR* hazard ratio, *IRI* irinotecan, *Ox* oxaliplatin, *PTX* paclitaxel

Publication bias {#Sec13}
----------------

Funnel plots did not show significant asymmetry and Egger's test was not significant for S-1-based therapy versus 5-FU/capecitabine-based therapy in terms of OS (*P* = 0.75), PFS (*P* = 0.82), and ORR (*P* = 0.73) and for S-1-based combination therapy versus S-1 monotherapy in terms of OS (*P* = 0.08), PFS (*P* = 0.71) and ORR (*P* = 0.96) (Figure S3).

Discussion {#Sec14}
==========

Previous meta-analyses have suggested that 5-FU may be replaced by S-1 in first-line therapy for advanced gastric cancer because of a survival benefit in favour of S-1 \[[@CR3], [@CR4]\]. Our updated meta-analysis does not confirm this finding. Although a higher ORR was observed for S-1-based therapy versus 5-FU-based therapy, OS and PFS were not significantly prolonged. The pooled OS and PFS effect sizes of the two recently conducted Western studies, the FLAGS and DIGEST trials, were comparable to the pooled OS and PFS effect sizes of all Asian studies. This suggests that S-1 may have similar efficacy in both Western and Asian patients. However, in Western patients S-1-based therapy did have clear clinically relevant advantages in terms of the toxicity profile over 5-FU-based therapy---namely, lower rates of febrile neutropenia, toxicity-related-deaths and grade 3--4 mucositis and stomatitis, whereas the toxicity profiles of S-1 and 5-FU in Asian patients showed no clinically relevant differences, except a higher rate of grade 3--4 fatigue and lower rates of grade 1--2 neutropenia and nausea. This indicates that S-1 is well tolerated in Western patients with its current dosing as used in the FLAGS and DIGEST trials.

Also, S-1 was not more effective than capecitabine in Asian patients. In the West, it has been suggested that capecitabine may be replaced by S-1 in the case of hand--foot syndrome. This meta-analysis shows that the incidence of grade 1--2 hand--foot syndrome was significantly lower with S-1 than with capecitabine. We stress that hand--foot syndrome specifically can have a severe impact on quality of life, because capacitabine is usually given for a longer time. Moreover, in a previous review which also included studies in metastatic colorectal cancer, a significantly lower rate of grade 3--4 hand--foot syndrome was observed for S-1 (0.3 %) compared with capecitabine (3.1 %); *P* \< 0.001 \[[@CR7]\]. Also, in our meta-analysis there were fewer observations of grade 3--4 hand--foot syndrome with S-1 (0.0 %) versus capecitabine (3.1 %), but the numbers were too low to reach statistical significance. Because all capecitabine studies were conducted in Asia, we should interpret our findings with caution for Western populations..

This is the first meta-analysis to examine the differential efficacy of combination therapy and monotherapy in patients with different baseline factors and can aid in clinical decision making. Overall, we showed that S-1 combination therapy is more efficacious than S-1 monotherapy. Importantly, our meta-analysis of stratified data from the three largest studies suggests that patients with disease characteristics associated with poor prognosis, such as non-measurable lesion, diffuse-type histological features and peritoneal metastasis, may have increased benefit from combination therapy.

The pooled result for the OS benefit of taxane combinations was not convincing because of heterogeneity. However, the HR (0.73) may be considered clinically meaningful and the PFS was significantly prolonged. Improvement of PFS may also be an important finding, because PFS is less prone to the influence of second-line therapy than OS. More grade 1--2 and grade 3--4 haematological toxicity as well as gastrointestinal toxicity occurred with combination therapy compared with monotherapy, which was in line with other combination chemotherapy regimens including a fluoropyrimidine combined with platinum compounds \[[@CR36], [@CR37]\], taxanes \[[@CR38], [@CR39]\] or irinotecan \[[@CR37], [@CR40]\].

Our study has some limitations. First, we did not take specific dosing regimens into account, which could have impacted our results. With pooled data analyses, including meta-analysis, it is often not possible to investigate to what extent dose differences may have influenced the results of the meta-analysis. Also, in some studies, leucovorin was added to fluoropyrimidine therapy. Leucovorin increases the intracellular pool of 5,10-methylenetetrahydrofolate, thereby enhancing thymidylate synthase inhibition by fluorodeoxyuridine monophosphate \[[@CR41]\]. This mechanism of action implies that leucovorin should be regarded not as an additional cytotoxic agent but rather as a modulator of fluoropyrimidine efficacy and toxicity. We conducted sensitivity analyses in which we omitted the studies in which leucovorin was concomitantly administrated with one of the S-1 or 5-FU regimens. This did not affect the pooled effect sizes of all comparisons. Furthermore, most of the fluoropyrimidine dosing regimens of the studies included in our review were similar. Especially the dosing of S-1 is fairly constant among different studies.

A second limitation is that the heterogeneity due to the difference in OS effect size in the Chinese subgroup and Japanese subgroup may somewhat complicate the interpretation of the S-1 combination therapy versus S-1 monotherapy analysis. Two of the Chinese studies were single-centre studies, whereas all Japanese studies were multicentre studies and therefore may have higher quality. However, the sensitivity analysis according to the risk of bias did not suggest major fluctuations in results. Whether there is a real difference in efficacy for combination therapy between Chinese and Japanese populations or whether this is purely a methodological issue remains unclear and should be addressed in larger and more qualitatively sound studies with Chinese patients.

In summary, S-1-based therapy showed no difference in survival compared with 5-FU- and capecitabine-based therapy but has a higher ORR compared with 5-FU-based therapy. In terms of clinical relevance, the toxicity profile of S-1 compared with 5-FU was clearly more advantageous in Western patients. Also, S-1 showed a better toxicity profile compared with capecitabine, with a lower incidence of hand--foot syndrome. In general, S-1 combination therapy is superior to S-1 monotherapy in terms of efficacy, and patients with poor prognosis disease characteristics may benefit most from S-1 combination therapy, although S-1 combinations were more toxic than S-1 alone. Our findings suggest that S-1-based regimens are effective and tolerable as first-line treatment of advanced gastric cancer in both Asian and Western countries.
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